HTLV-1 and HTLV-2 Differentiation via Oligonucleotide Probes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for HTLV-1 and HTLV-2 infections face challenges such as high costs, inefficiency, and inability to differentiate between the two viruses, leading to inconclusive results and false positives, particularly during the pre-seroconversion period or in cases of immunological window periods.
Innovation Solution
Development of oligonucleotides and diagnostic kits using real-time PCR technology that can detect and discriminate HTLV-1 and HTLV-2 in a single reaction, incorporating specific primers and probes designed for the pol region of the virus, with thorough validation processes to ensure sensitivity, specificity, and reproducibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If serological tests are used for HTLV-1/2 screening, then the transmission risk can be monitored, but the tests are insufficient for differentiation between HTLV-1 and HTLV-2 infections
Solution Approach 1:
The patent divides the diagnostic process into two distinct stages: screening using serological tests for initial detection, and confirmation using type-specific PCR assays for differentiation. This segmentation allows each test to optimize for its specific function - serological tests for sensitivity in screening, and PCR for specificity in differentiation between HTLV-1 and HTLV-2
Solution Approach 2:
The patent introduces type-specific oligonucleotide primers and probes as intermediary elements that bridge the gap between general HTLV detection and specific virus type differentiation. These intermediaries enable the diagnostic system to distinguish between HTLV-1 and HTLV-2 by targeting unique sequence regions in each virus type
2Measurement precision
If confirmatory testing is performed to differentiate HTLV-1 and HTLV-2, then diagnostic precision improves, but the cost and time consumption increase
Solution Approach 1:
The patent combines multiple diagnostic functions into a single integrated workflow: serological screening followed by type-specific PCR confirmation. By merging the differentiation function into the confirmation stage using highly specific oligonucleotide probes, the system achieves accurate virus type identification without requiring separate lengthy testing protocols
Solution Approach 2:
The patent changes the detection parameter from general antibody presence (serology) to specific viral sequence detection (PCR). This parameter change enables precise virus type differentiation through type-specific primers and probes, achieving both accuracy and efficiency by targeting unique genomic regions of HTLV-1 and HTLV-2
3Adaptability or versatility
If type-specific oligonucleotides are designed for PCR detection, then virus differentiation capability improves, but the device complexity increases
Solution Approach 1:
The patent applies local quality by designing oligonucleotide primers and probes with specific sequence characteristics tailored to each virus type. Each oligonucleotide is locally optimized to bind exclusively to HTLV-1 or HTLV-2 unique sequences, enabling differentiation through targeted molecular recognition rather than complex instrumental differentiation
Solution Approach 2:
Instead of using complex instrumental methods to differentiate viruses, the patent inverts the approach by embedding the differentiation capability directly into the oligonucleotide sequences themselves. The type-specific sequences act as built-in identifiers that simplify the detection system while maintaining high discrimination capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides accurate, rapid, and cost-effective detection and differentiation of HTLV-1 and HTLV-2 infections, reducing false positives and inconclusive results, and is capable of detecting infections during the immunological window period.
Implementation Method 1
an oligonucleotide capable of binding to the pol region of HTLV and being suitable as primer
Implementation Method 2
Development of oligonucleotides and diagnostic kits using real-time PCR technology that can detect and discriminate HTLV-1 and HTLV-2
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The presence of human T-cell lymphotropic virus (HTLV) can be detected and the virus can be typed as type 1 or 2 by the method described herein, which involves amplification of HTLV DNA sequences by real-time polymerase chain reaction. To this end, primers used to amplify a particular region of the HTLV1 and 2 genome were developed. The presence of HTLV-1 and/or HTLV-2 in a sample is indicated by the generation of fluorescence released by the specific probes for each subtype.